Priya Rastogi

11PUBLICATIONS
122CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 17, 2026
Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.

|Jun 25, 2026
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

|Dec 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.

Yara Abdou, William E Barlow, Julie R Gralow

|Aug 11, 2024
Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials.

Julia Foldi, Neil Carleton, Stewart J Anderson

|Jul 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.

Priya Rastogi, Hanna Bandos, Peter C Lucas

|Jun 04, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.

Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai

Pageof 2

Frequent Collaborators

6 joint publications

Charles E Geyer

5 joint publications

Norman Wolmark

5 joint publications

Eleftherios P Mamounas

3 joint publications

Priyanka Sharma